SCHEMBL2882973

SCHEMBL2882973

Cn1ccc(C2CCN(Cc3ccc(C(=NOCC#N)c4ccc(F)c(F)c4)nc3)CC2)cc1=O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 6/20 0.53
KCNH2 Q12809 4/20 0.53
DRD2 P14416 2/20 0.36
ADRA1A P35348 2/20 0.36
PRKAA2 P54646 9/20 0.35
PIK3CA P42336 3/20 0.35
PARP1 P09874 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PRKAB2 O43741 5/20 0.33
PRKAG1 P54619 5/20 0.33
PRKAA1 Q13131 5/20 0.33
PRKAG3 Q9UGI9 5/20 0.33
PRKAG2 Q9UGJ0 5/20 0.33
PRKAB1 Q9Y478 5/20 0.33
DRD4 P21917 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2882971 1.00 MCHR1 (0.53) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2885432 0.91 MCHR1 (0.63) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2885433 0.91 MCHR1 (0.63) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2880878 0.86 MCHR1 (0.49) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2880881 0.86 MCHR1 (0.49) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2877665 0.86 MCHR1 (0.50) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2877663 0.86 MCHR1 (0.50) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2882559 0.86 MCHR1 (0.50) MCHR1KCNH2DRD2ADRA1APRKAA2
SCHEMBL2883338 0.85 MCHR1 (0.46) MCHR1KCNH2PRKAA2PRKAB2PRKAG1
SCHEMBL2883335 0.85 MCHR1 (0.46) MCHR1KCNH2PRKAA2PRKAB2PRKAG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MSD K.K. (JP) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MC1R, MCHR1, MCHR2 MCHR1 2/4885KCNH2 565/4885DRD2 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.